CME / ABIM MOC / CE

Hot Topics in ADHD: Expert Poster Presentation Session

Authors: Joseph Biederman, MD; Ann C. Childress, MD; Andrew J. Cutler, MD; Vladimir Maletic, MD, MS; Stephen V. Faraone, PhD; Takuya Saito, MD, PhD
CME / ABIM MOC / CE Released: 6/29/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/29/2022, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care clinicians, nurses and pediatricians.

The goal of this activity is to highlight the hot topics related to attention-deficit/hyperactivity disorder (ADHD) presented directly from the experts who are presenting posters/oral abstracts at APSARD 2021 and the annual meeting of the American Psychiatric Association (APA 2021; virtual conference held May 1-5, 2021).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Emerging clinical data on ADHD treatments at early 2021 conferences
- Mechanisms of action (MOAs) of new treatment options for ADHD in the context of disease neurobiology therapeutic advances in ADHD that will be presented at 2021 conferences

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Joseph Biederman, MD

Department of Respiratory Medicine
Medizinische Hoschschule Hannover
and German Centre of Lung Research (DZL)
Hannover, Germany

Disclosures

Disclosure: Joseph Biederman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Cowen Healthcare Investments
Served as a speaker or a member of a speakers bureau for: Institute of Integrated Sciences; Multi-Health Systems; Tris
Received grants for clinical research from: Genentech; Headspace, Inc.; Pfizer; Roche TCRC Inc.; Shire; Sunovion; Takeda; Tris
Royalties or patent beneficiary: Biomarin; Bracket Global; Cogstate; Ingeni; Medavent Prophase; Shire; Sunovion; Theravance
Other: Partnership with MEMOTEXT for digital health intervention. Through Massachusetts General Hospital corporate licensing, Dr. Biederman has a US Patent (#14/027,676) for a non-stimulant treatment for ADHD, a US Patent (#10,245,271 B2) on a treatment of impaired cognitive flexibility, and a patent pending (#61/233,686) on a method to prevent stimulant abuse.

Ann C. Childress, MD

Adjunct Faculty
UNLV School of Medicine &
Touro University of Nevada, College of Medicine
President
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada, United States

Disclosures

Disclosure: Ann C. Childress, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adlon; Akili; Arbor; Cingulate; Corium; Ironshore; Jazz; KemPharm; Neos; Otsuka; Pharma; Purdue; Receptor; Rhodes; Shire; Sunovion; Supernus; Tris; Tulex Pharma
Served as a speaker or a member of a speakers bureau for: Ironshore; Neos; Shire; Supernus; Takeda; Tris
Received grants for clinical research from: Adlon; Akili; Allergan; Arbor; Emalex; KemPharm; Neos; Otsuka; Purdue; Rhodes; Servier; Shire; Sunovion; Supernus; Takeda; Tris

Andrew J. Cutler, MD

Clinical Associate Professor of Psychiatry
SUNY Upstate Medical University
Syracuse, New York, United States

Disclosures

Disclosure: Andrew J. Cutler, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Acadia; AiCure; Alfasigma; Alkermes; Allergan; Atentive; Cognitive Research; Intra-Cellular Therapies; Ironshore; Janssen; Lundbeck; MedAvante-Prophase; Neurocrine; Noven; Otsuka; Sage; Sunovion; Supernus; Takeda; Teva
Served as a speaker or a member of a speakers bureau for: AbbVie; Acadia; Alfasigma; Alkermes; Allergan; Intra-Cellular Therapies; Ironshore; Janssen; Lundbeck; Neurocrine; Noven; Otsuka; Sunovion; Supernus; Takeda; Teva; Tris

Vladimir Maletic, MD, MS

Clinical Professor
Neuropsychiatry and Behavioral Science
University of South Carolina
School of Medicine
Columbia, South Carolina, United States

Disclosures

Disclosure: Vladimir Maletic, MD, MS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Acadia; Alfasigma; Allergan; Eisai; Intra-Cellular; Lundbeck A/S; Merck; Otsuka America; Shire; Sunovion; Supernus; Takeda; Teva
Served as a speaker or a member of a speakers bureau for: AbbVie; Alkermes; Allergan; Eisais; Intra-Cellular Therapies; Ironshore; Lundbeck A/S; Merck; Otsuka America; Sunovion; Supernus; Takeda

Stephen V. Faraone, PhD

Distinguished Professor in the
Departments of Psychiatry and
Neuroscience & Physiology
Vice Chair for Research for the
Department of Psychiatry
SUNY Upstate Medical University
Syracuse, New York, United States

Disclosures

Disclosure: Stephen V. Faraone, PhD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Akili; Arbor; Genomind; Ironshore; OnDosis; Otsuka; Rhodes; Sunovion; Supernus; Takeda; Tris
Other: With his institution (SUNY Upstate Medical University), he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD

Takuya Saito, MD, PhD

Professor
Department of Child and Adolescent Psychiatry
Graduate School of Medicine
Hokkaido University
Sapporo, Hokkaido, Japan

Disclosures

Disclosure: Takuya Saito, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Mochida; Sumitomo-Dainippon; Taisho; Takeda; Viatris
Served as a speaker or a member of a speakers bureau for: Janssen; Shionogi
Received grants for clinical research from: Otsuka

Editor

Clinton W. Wright, PharmD, BCPP

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Clinton W. Wright, PharmD, BCPP, has disclosed no relevant financial relationships.

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

ADHD Learning Destination

From Medscape Education Psychiatry & Mental Health

CME / ABIM MOC / CE

Hot Topics in ADHD: Expert Poster Presentation Session

Authors: Joseph Biederman, MD; Ann C. Childress, MD; Andrew J. Cutler, MD; Vladimir Maletic, MD, MS; Stephen V. Faraone, PhD; Takuya Saito, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 6/29/2021

Valid for credit through: 6/29/2022, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

A Novel SMS Intervention to Improve Adherence to Stimulants in Adults With ADHD in the Primary Care Setting

Joseph Biederman, MD

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4 to 5 Years Old With Attention-Deficit/Hyperactivity Disorder

Ann C. Childress, MD

Efficacy and Safety of KP415 (Serdexmethylphenidate and d-Methylphenidate) Capsules in Children With ADHD: A Randomized, Double-Blind, Placebo-Controlled Laboratory Classroom Study

Andrew Cutler, MD

Mechanism of Action of Viloxazine: Effects on Norepinephrine and Serotonin

Vladamir Maletic, MD

SPN-812 (Viloxazine Extended-Release): Post Hoc Analyses Evaluating Clinical Significance and Predictions of Efficacy

Stephen V. Faraone, PhD

Tipepidine Hibenzate Sustained-Release Tablet (TS-141), for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Takuya Saito, MD, PhD

Page 1 of 7

A Novel SMS Intervention to Improve Adherence to Stimulants in Adults With ADHD in the Primary Care Setting

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Joseph Biederman, MD

Ann C. Childress, MD

Andrew J. Cutler, MD

Vladimir Maletic, MD, MS

Stephen V. Faraone, PhD

Takuya Saito, MD, PhD

Editor

Clinton W. Wright, PharmD, BCPP

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Hot Topics in ADHD: Expert Poster Presentation Session

Target Audience and Goal Statement

Disclosures

Faculty

Joseph Biederman, MD

Ann C. Childress, MD

Andrew J. Cutler, MD

Vladimir Maletic, MD, MS

Stephen V. Faraone, PhD

Takuya Saito, MD, PhD

Editor

Clinton W. Wright, PharmD, BCPP

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Hot Topics in ADHD: Expert Poster Presentation Session

Contents of This CME Activity

A Novel SMS Intervention to Improve Adherence to Stimulants in Adults With ADHD in the Primary Care Setting

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4 to 5 Years Old With Attention-Deficit/Hyperactivity Disorder

Efficacy and Safety of KP415 (Serdexmethylphenidate and d-Methylphenidate) Capsules in Children With ADHD: A Randomized, Double-Blind, Placebo-Controlled Laboratory Classroom Study

Mechanism of Action of Viloxazine: Effects on Norepinephrine and Serotonin

SPN-812 (Viloxazine Extended-Release): Post Hoc Analyses Evaluating Clinical Significance and Predictions of Efficacy

Tipepidine Hibenzate Sustained-Release Tablet (TS-141), for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder